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Publication of this report would not have been possible without the voluntary participation of the
Association of Public Health Laboratories members, California Public Health Laboratories members and
Infertility Prevention Project laboratories.
The following staff and contractors of the Centers for Disease Control and Prevention and Association of
Public Health Laboratories staff were responsible for the development of the web-based survey, survey
administration, analysis of the data, and preparation of this report: Kumar Batra, Scott Becker, Jim
Braxton, John Douglas, Jerri Givens, Bob Johnson, Mark Lamais, John Papp, Catherine Satterwhite,
Richard Steece, Robin Tracy, Anthony Tran, Hillard Weinstock, and Eileen Yee.
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This report provides a summary of the responses received from a web-based survey conducted among
public health laboratories on the volume and type of testing for sexually transmitted diseases in the
United States in 2007. The survey was conducted in January 2008, and responses were received from
61.4% (94 of 153) of all invited participants.
Overall in 2007, 3,290,390 chlamydia tests and 3,157,827gonorrhea tests were performed in surveyed
laboratories; 89.7% of chlamydia tests and 84.4% of gonorrhea tests were nucleic acid amplification tests
(NAATs).
Of the 90 labs reporting any gonorrhea testing, 52.1% reported performing gonorrhea culture. Among the
surveyed laboratories that reported doing gonorrhea testing, but reported having no culture capacity,
33.3% had access to gonorrhea culture for medical-legal purposes.
Over 90% of surveyed laboratories reported conducting syphilis testing. Of the 49 public health
laboratories that reported doing herpes testing (79,614 total tests), 71.4% reported doing standard cell
culture, and 30.6% of labs performed the HerpesSelect test (type-specific serology). Only 14 labs
reported performing any trichomonas testing, and the majority of tests were culture based. Only 10 labs
reported performing any bacterial vaginosis testing. Three labs performed 3,315 human papillomavirus
tests and 5 labs reported doing pap smears, of which the majority was using liquid-based cytology.
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In the United States, about 18.9 million people become infected with one or more sexually transmitted
infections each year, often causing severe consequences and adding substantially to healthcare costs.
Sexually transmitted diseases (STDs) are one of the most under-recognized health problems.
Laboratory technology to detect STDs is ever evolving. To better understand current laboratory test
usage and procedures, the Centers for Diseases Control and Prevention, Division of STD Prevention,
with assistance from the Association of Public Health Laboratories (APHL), surveyed public health
laboratories throughout the U.S. in January 2008. The purpose of the survey was to collect information
about the volume and type of testing for STDs in the U.S. in 2007. A similar survey was conducted in
February 2005 and in February 2001 (Dicker LW, Mosure DJ, Steece R, Stone KM. Testing for Sexually
Transmitted Diseases in U.S. Public Health Laboratories in 2004. Sex Transm Dis 2007;34(1):41-46 and
Dicker LW, Mosure DJ, Steece R, Stone KM. Laboratory Tests Used in US Public Health Laboratories for
Sexually Transmitted Diseases, 2000. Sex Transm Dis 2004;31(5):259-264). This summary report




State and local members of the Association of Public Health Laboratories (APHL), members of the
California Association of Public Health Laboratory Directors (CAPHLD), and laboratories participating in
the Infertility Prevention Project (IPP) were included in this survey.
Construction of Survey Instrument
A web-based survey was developed using the previous 2004 survey instrument as a template. Questions
were designed to allow for comparisons with those data previously collected. The survey received OMB
clearance (PRA 0920-0677). In addition, the survey was considered non-research and exempt from IRB.
Survey Administration
An email was sent to the laboratory directors that included a letter of introduction and a direct link to the
web-based survey with a unique userID and password to access the survey. If there was any difficulty
transmitting the email, then a fax or scanned version of the survey questions was sent to the laboratory
director. The laboratories were asked initially to respond in 4 weeks. Due to several technical problems
with the survey instrument, completed surveys were accepted up to 8 weeks after release. Follow-up
reminders were sent via email to non-responders at weeks 3, 5, and 7.
Data Analysis
This survey and analysis focused on the types of STD testing used and testing volumes in the U.S. in
laboratories that participated in this survey. Tables were produced describing the number of laboratories
that reported performing each of the laboratory tests listed in the survey, as well as summarizing the
quantity of the tests conducted.
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The questions for this survey were modeled after questionnaires from previous surveys in an effort to
increase the utility of the data and add considerably to the general body of knowledge about STD testing.
This survey was also updated to reflect current market availability of STD test technology. Laboratories
were asked to provide testing and volume information for the prior year (2007). Some laboratories were
unable to provide specific test volume details from the prior year. In addition, for laboratories that
reported performing “other” tests, we did not have any additional information on the specific type of tests.
Some laboratories reported tests that had not been FDA- cleared for specific use for specimens from
different anatomical sites; however, we assumed that each laboratory conducted their own verification
study and had CLIA-approval to perform these tests.
RESULTS
Response Rate
153 public health laboratories were invited to participate in this survey. The survey was completed by 94
of 153 public health laboratories, for an overall response rate of 61.4%.
Description of Respondents
Of the laboratories that responded to the survey, 71% were members of APHL, 19% were members of
CAPHLD, and 23% were laboratories participating in IPP. The percentages can add up to more than




                                                                         
               









            
         
            
             
              
                
                
               
         
             
              
                    
                   
                   
                         
               
               
                
               
                 






    
           
                      
                
 
                   
              




















Any CT testing 87 of 94 (92.6) 3,290,390 582,265 (17.7) 424,316 (12.9)
Non-NAAT* 524,947 (16.0) 30 (0.0) 108,550 (25.6)
Culture 10 (11.5) 2,379 (0.1) --­ 2 (0.0)
DFA 3 (3.4) 245 (0.0) --­ --­
EIA 2 (2.3) 62,420 (1.9) 30 (0.0) --­
Hybrid Capture 2 (Digene) 1 (1.1) 47,402 (1.4) --­ --­
PACE 2 (Gen-Probe) 13 (14.9) 109,681 (3.3) --­ 17,510 (4.1)
PACE 2C ( Gen-Probe) 11 (12.6) 302,820 (9.2) --­ 91,038 (21.4)
NAAT** 2,684,278 (81.6) 578,882 (99.4) 312,284 (73.6)
SDA (Becton Dickinson) 28 (32.2) 844,093 (25.7) 242,422 (41.6) 265,684 (62.6)
Aptima Combo 2 (Gen-Probe) 51 (58.6) 1,747,651 (53.1) 303,558 (52.1) 45,074 (10.6)
Aptima CT(Gen-Probe) 8 (9.2) 46,643 (1.4) 13,813 (2.4) 1,526 (0.4)
PCR COBAS Amplicor (Roche) 2 (2.3) 34,802 (1.1) 8,000 (1.4) --­
PCR Amplicor MWP (Roche) 1 (1.1) 11,089 (0.3) 11,089 (1.9) --­
Serology 84 (0.0)
CF 0 (0.0) 0 (0.0)
IFA 2 (2.3) 67 (0.0)
MIF 1 (1.1) 7 0.0)
Serology-Other 1 (1.1) 10 (0.0)
Other Antigen Tests 5 (5.7) 81,081 (2.4) 3,353 (0.6) 3,482 (0.8)
     Access to CT Culture for Med­
 legal Purposes    
Yes    18 (20.7)
  
    No/Did Not Answer/Missing
   69 (79.3) 
CT=Chlamydia
NAAT=Nucleic acid amplification test
* 27 labs reported doing at least 1 type of non-NAAT.
 
** 78 labs reported doing at least 1 type of NAAT; 67 labs reported only performing 1 type of NAAT; 11 labs
 
reported performing >1 type of NAAT. Labs may have reported both non-NAATs and NAATs.

†
Some urine and vaginal swab tests may have been reported erroneously. Cells shaded in gray represent test and
 
specimen combinations not explicitly FDA-cleared. Participating labs may have performed independent verification.





                                                                         
              









            
           
                 
                  
                
                  
          
             
              
                     
                   
                   
                   
 
          
    
    
    
    
    
            
 
 
    
           
                       
      
 
                   
              
          
                














Any GC testing 90 of 94 (95.7) 3,157,827 556,337 (18.6) 406,653 (12.7)
Non-NAAT* 560,128 (17.7) 12,538 (2.1) 91,159 (22.4)
Culture 49 (54.4) 157,294 (4.9) 10 (0.0) 659 (0.2)
Hybrid Capture 2 (Digene) 0 (0.0) 0 (0.0)
PACE 2 (Gen-Probe) 13 (14.4) 89,894 (2.8) --­ 2,395 (0.6)
PACE 2C ( Gen-Probe) 11 (12.2) 312,940 (9.7) 12,528 (2.1) 88,105 (21.7)
NAAT** 2,524,382 (80.0) 540,446 (97.1) 312,012 (76.7)
SDA (Becton Dickinson) 26 (28.9) 755,958 (23.4) 218,227 (39.2) 260,944 (64.2)
Aptima Combo 2 (Gen-Probe) 53 (58.9) 1,733,430 (53.8) 312,924 (56.2) 51,067 (12.6)
Aptima GC (Gen-Probe) 4 (4.4) 12,414 (0.4) 15 (0.0) 1 (0.0)
PCR COBAS Amplicor (Roche) 1 (1.1) 18,300 (0.6) 5,000 (0.9) --­
PCR Amplicor MWP (Roche) 1 (1.1) 4,280 (0.1) 4,280 (0.8) --­
Other Antigen Tests 4 (4.4) 73,317 (2.3) 3,353 (0.6) 3,482 (0.9)
Anatomical Culture Sites
‡ 
Total Labs (%) Total Tests
Cervical 41 (83.7) 11,739
Urethral 41 (83.7) 14,235
Rectal 42 (85.7) 12,220
Pharyngeal 42 (85.7) 28,255
Other 14 (28.6) 258
Total 49 66,707
     Access to GC Culture for Med­
 legal Purposes   
Yes   33 (36.7)
 
 No/NA
  57 (63.3) 
 
GC=Gonorrhea
NAAT=Nucleic acid amplification test
* 55 labs reported doing at least 1 type of non-NAAT.
 
** 76 labs reported doing at least 1 type of NAAT; 67 labs reported only performing 1 type of NAAT; 9 labs reported
 
performing >1 type of NAAT.

†
Some urine and vaginal swab tests may have been reported erroneously. Cells shaded in gray represent test and
 
specimen combinations not explicitly FDA-cleared. Participating labs may have performed independent verification.

Data shown in this table are as reported.

‡Anatomical culture site was only reported for 66,707 tests out of 157,294 total culture tests (42.4%).
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Table 3. Type and Number of Gonococcal Antimicrobial Susceptibility Tests Performed in

Public Health Laboratories, 2007
 
  Labs Reporting   Total Tests
    Testing (%)  Reported (%) 
 Any AST    29 of 49 (59.2)   
   Agar Dilution    1 (3.4)   107  (0.4) 
    Disk Diffusion  20 (69.0)  14,668 (53.5) 
   E-Test  11 (37.9)  2,760 (10.1) 
   β-lactamase  7 (24.1)  9,861 (36.0) 
  Other    0 (0.0)    0 (0.0) 




   
   
   
   
   
     
   
     
     
   
   
   
   





































                                                                         


























   
  
   
    
   
   
  
   
  
  













        
         
            
              
              
      
            
          
          
              
             
              
               
        
                 
            
             
               
            
                
               
               
               






Any Syphilis Test 88 of 94 (93.6) 1,978,172
Direct Detection 1,358 (0.1)
Dark-field 15 (17.0) 1,176 (0.1)
DFA-TP 5 (5.7) 167 (0.0)
PCR 1 (1.1) 15 (0.0)
Non-Treponemal 1,785,000 (90.2)
VDRL 37 (42.0) 131,349 (6.6)
RPR-qualitative 62 (70.5) 1,251,866 (63.3)
RPR-quantitative 65 (73.9) 260,432 (13.2)
USR 3 (3.4) 24,180 (1.2)
Stat RPR 9 (10.2) 14,345 (0.7)
Trust 2 (2.3) 102,792 (5.2)
Other Non-Treponemal 2 (2.3) 36 (0.0)
Treponemal 191,814 (9.7)
Captia Syphilis G (EIA) 6 (6.8) 57,624 (2.9)
FTA-ABS 27 (30.7) 44,469 (2.2)
FTA-ABS DS 14 (15.9) 15,450 (0.8)
Inno-LIA (Immunoblot) 2 (2.3) 10 (0.0)
TP-PA 49 (55.7) 50,790 (2.6)
Trep-Chek IgG (EIA) 4 (4.5) 8,752 (0.4)
Trep-Sure (EIA) 3 (3.4) 5,117 (0.3)
Western Blot 3 (3.4) 76 (0.0)











TP-PA=Treponema pallidium particle agglutination
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Herpes Simplex Virus (HSV) 49 of 94 (52.1) 79,614
Culture
Standard cell Culture 35 (71.4) 26,817 (33.7)
Shell Vials 13 (26.5) 5,836 (7.3)
Direct Detection
DFA 18 (36.7) 6,787 (8.5)
Roche Lightcycler (PCR) 9 (18.4) 4,268 (5.4)
Tzanck 0 (0.0) 0 (0.0)
Other (Specify) 5 (10.2) 0 (0.0)
Serology
Type-Specific
HerpesSelect (Focus Technology) 15 (30.6) 22,085 (27.8)
Fisher SureVue Bioki-HSV-2 1 (2.0) 575 (0.7)
Western Blot 1 (2.0) 105 (0.1)
Other 8 (16.3) 13,141 (16.5)
Trichomonas 14 of 94 (4.8) 22,115
Affirm VP
DFA 0 (0.0) 0 (0.0)
PCR 0 (0.0) 0 (0.0)
Xenostrip-TV 0 (0.0) 0 (0.0)
Culture 0 (0.0) 0 (0.0)
In Pouch 2 (14.3) 646 (2.9)
Other 12 (85.7) 21,469 (97.1)
Bacterial Vaginosis (BV) 10 of 94 (10.6) 22,177
Affirm VP 0 (0.0) 0 (0.0)
Gram Stain 10 (100.0) 22,177 (100.0)
Human Papillomavirus (HPV) 3 of 94 (3.2) 3,315
Hybrid Capture 2 High-Risk Probe 2 (66.7) 1,529 (46.1)
Hybrid Capture 2 Low-Risk Probe 1 (33.3) 100 (3.0)
Other HPV test 1 (33.3) 1,686 (50.9)
Pap Smears 5 of 94 (5.3) 190,301
Conventional 2 (40.0) 37,436 (19.7)
Liquid-based Cytology
ThinPrep 4 (80.0) 127,996 (67.3)
SurePath 2 (40.0) 24,869 (13.0)
Other 0 (0.0) 0 (0.0)





                                                                         
 
 
               
                
                  
               
                  
CONCLUSION
This survey documented the types and number of sexually transmitted disease tests performed in public
health laboratories in the United States in 2007. Further analysis will be performed to compare testing
practices from similar surveys done in 2000 and 2004. It is important to continue to monitor the capacity
of public health laboratories to appropriately test for STDs, and ongoing monitoring of testing practices
should be an important part of our efforts to reduce the prevalence and consequences of these diseases.
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